Table 1.
Donor and Recipient Characteristics for Adult Heart Transplants Performed January 1, 2010 – June 30, 2018
| Donor and Recipient Characteristics | (N = 36,883) |
|---|---|
| Recipient age (years) | 55.0 (25.0–68.0) |
| Donor age (years) | 35.0 (17.0–58.0) |
| Donor and recipient age difference (years) | −16.0 (−43.0 to 13.0) |
| Recipient weight (kg) | 80.1 (54.0–109.8) |
| Recipient height (cm) | 174.0 (157.0–188.0) |
| Recipient body mass index | 26.5 (19.5–34.9) |
| Donor weight (kg) | 80.0 (57.0–115.2) |
| Donor height (cm) | 175.0 (157.5–188.0) |
| Donor body mass index (kg/m2) | 26.0 (19.9–37.5) |
| Donor/recipient sex (% male) | 67.9%/74.4% |
| Female donor-to-male recipient | 16.10% |
| Male donor-to- female recipient | 9.70% |
| Donor/recipient diabetes mellitus | 3.5%/26.9% |
| Recipient history of prior dialysis | 4.80% |
| Donor/recipient cigarette history | 14.5%/44.9% |
| Donor/recipient hypertension | 15.4%/51.1% |
| Recipient prior cardiac surgery | 50.30% |
| Recipient previous malignancy | 8.60% |
| Ischemic time (hours) | 3.2 (1.5–5.0) |
| Panel reactive antibody > 10%a | 22.0% |
| Panel reactive antibody (%)a | 0.0 (0.0–71.0) |
| Creatinine at time of transplant (mg/dl) | 1.2 (0.7–2.3) |
| Pulmonary vascular resistance (Wood units) | 2.0 (0.0–5.3) |
| HLA mismatches | |
| 0–2 | 3.9% |
| 3–4 | 38.2% |
| 5–6 | 57.9% |
| Diagnosis | |
| Congenital heart disease | 3.1% |
| Hypertrophic cardiomyopathy | 3.4% |
| Ischemic cardiomyopathy | 32.4% |
| Non-ischemic cardiomyopathy | 50.8% |
| Restrictive cardiomyopathy | 3.5% |
| Retransplant | 2.8% |
| Valvular cardiomyopathy | 2.5% |
| Other | 1.5% |
| Donor cause of death | |
| Head trauma | 40.5% |
| Stroke | 19.9% |
| Anoxia | 21.5% |
| Central nervous system tumor | 0.5% |
| Other | 17.7% |
| Pre-operative support (multiple items may be reported) | |
| Hospitalized at time of transplant | 44.5% |
| On intravenous inotropes | 39.1% |
| Ventilator | 1.7% |
| Intra-aortic balloon pump | 7.3% |
| Mechanical circulatory support | 45.1% |
| Left ventricular assist device | 42.9% |
| Right ventricular assist device | 2.9% |
| Total artificial heart | 1.3% |
| Extracorporeal membrane oxygenation | 1.2% |
Continuous Factors Are Reported as Median (50th–95th Percentiles).
a
Panel reactive antibody includes Panel reactive antibody or Calculated panel reactive antibody values as reported by the centers. If Class I and Class II Panel reactive antibody values were reported separately, the higher of the 2 values was used.